Grosh W W, Jones H W, Burnett L S, Greco F A
Gynecol Oncol. 1986 Nov;25(3):334-9. doi: 10.1016/0090-8258(86)90084-3.
Twelve patients with malignant mixed mullerian tumors were treated with combination chemotherapy at Vanderbilt University Hospital from 1977 through 1981. Nine patients, all of whom received combination chemotherapy with hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (HCAP), were evaluable for response. Objective responses (all partial responses) were noted in 3 (33.3%) (response rate greater than 10% and less than 55% with 90% confidence limits), a minimal response was noted in one patient, and stable disease in four (50%) patients. Responders survived longer (calculated from the initiation of HCAP) than nonresponders (median 112 vs 19 weeks). These results are not at present statistically different from previous studies utilizing doxorubicin alone, cisplatin alone, the combination of doxorubicin and DTIC, or the combination of vincristine, actinomycin D, and cyclophosphamide.
1977年至1981年期间，范德比尔特大学医院对12例恶性苗勒管混合瘤患者进行了联合化疗。9例患者接受了六甲蜜胺、环磷酰胺、多柔比星和顺铂（HCAP）联合化疗，可评估其反应。观察到3例（33.3%）有客观反应（均为部分反应）（反应率大于10%且小于55%，90%置信区间），1例患者有微小反应，4例（50%）患者病情稳定。反应者（从开始使用HCAP计算）的生存期比无反应者长（中位数分别为112周和19周）。目前这些结果与之前单独使用多柔比星、单独使用顺铂、多柔比星与达卡巴嗪联合使用，或长春新碱、放线菌素D和环磷酰胺联合使用的研究在统计学上没有差异。
